Zoetis and Abaxis Announce Antitrust Clearance for Merger
On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Exploring Abaxis’s Financial Performance
In fiscal 3Q18, the total revenues generated by Abaxis (ABAX) were $59.6 million compared to $52.7 million in fiscal 3Q17.
A Look at the Performances of Abaxis’s Product Categories
Abaxis (ABAX) markets its products under three categories: instruments, consumables, and other products.
An Insight into Abaxis’s Business Segments
In the medical market, Abaxis (ABAX) targets physicians’ offices across multiple specialties.
Analysts’ Ratings for Abaxis and Its Peers in February 2018
Of the ten analysts covering Abaxis in February 2018, two gave the stock “strong buys,” six gave it “holds,” and two gave it “sells.”